📋 ALPINE IMMUNE SCIENCES, INC. (ALPN) - Other Event
Filing Date: 2022-05-24
Accepted: 2022-05-24 08:23:01
Event Type: Other Event
Event Details:
Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024) (ALPN) Provides Business Update
Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024) (ALPN) issued a business update covering recent developments.
🔍 Detailed Event Analysis:
AI Summary: Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is developing Davoceticept in Combination with Pembrolizumab. The trial is expected to be completed by May 24, 2022. The company is based in Seattle, Washington.
Key Elements Identified:
Drugs/Compounds: treatments, pembrolizumab
Clinical Trials: Clinical Trial
Organizations: nowrap">NEON-2 Clinical Trial of Davoceticept, the Company’s Complete Response, ALPN
💼 Business Developments:
No business developments data available.
Structured Data:
Company Name: Alpine Immune Sciences Inc (was acquired Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) on 10/04/2024)
📋 ALPINE IMMUNE SCIENCES, INC. (ALPN) - Other Event
Filing Date: 2022-05-24
Accepted: 2022-05-24 08:23:01
Event Type: Other Event
Event Details:
🔍 Detailed Event Analysis:
AI Summary: Alpine Immune Sciences, Inc. (NASDAQ: ALPN) is developing Davoceticept in Combination with Pembrolizumab. The trial is expected to be completed by May 24, 2022. The company is based in Seattle, Washington.
Key Elements Identified:
💼 Business Developments:
No business developments data available.
Structured Data: